Stock information

General information

Total Shares Issued (as of end December, 2019) 31,957,958
Designated Sponsor/Market Maker: Oddo Seydler Bank AG
Reuters: MORG.DE
Bloomberg MOR:GR
Paying Agent Deutsche Bank AG
Global Securities Services
lssuer Services / Post IPO Seruices
Taunusanlage 12
60325 Frankfurt am Main

listing in Germany

Stock Exchange: Frankfurt, Germany (Prime Standard)
Index: MDAX & TecDAX
SE Code: MOR
Security Code Number: 663 200
ISIN (International Security Identification Number): DE0006632003
1st Trading Day: March 9, 1999 (Neuer Markt)

Listing in the u.s.

Stock Exchange: Nasdaq
SE Code: MOR
CUSIP: 61776020
1st Trading Day: April 19, 2018
Security Paper: American Depositary Shares (ADS)
Ratio: 4 ADS = 1 Ordinary Share


Stock charts

Share price performance

MorphoSys AG shares opened the reporting year at a share price of € 76.58. After a solid start in the first weeks of 2018, the share price dropped in line with the TecDax due to weak trends observed on Wall Street affecting the European markets and MorphoSys’s share reached its low for the year of € 72.05 mid-February. The shares then trended higher in line with the TecDAX before breaking out in April after the Company announced the initial public offering in the United States and the listing of ADSs on the Nasdaq Global Market. From April 9 on, the share price constantly increased, far outpacing the benchmark index. The dual listing as well as positive news flow, such as approval of Tremfya® for plaque psoriasis in new regions and also for psoriatic arthritis in Japan received by Janssen in June as well as the global licensing agreement with Novartis and Galapagos for MOR106 mid-July, drove MorphoSys shares to a high of €122.20 on July 24. Thereafter, the worldwide stock markets were affected by the U.S. trade war with China and by the jump in returns in the U.S. Moreover, the European Market was marked by insecurities due to the banking crisis in Italy, with all causing a continuous decline for both the TecDAX as well as the MorphoSys shares. This resulted in a low of € 77.75 on October 26. Of note, MorphoSys shares were included into the MDAX as of September 24 while remaining part of the TecDAX segment. The simultaneous inclusion in both indices, MDAX and TecDAX, was based on the reorganization of the index rules of Deutsche Börse, the existing separation into the Tech and Classic segments having been removed. While both the TecDAX and MDAX declined further in the course of the year, MorphoSys’s share price again increased from the beginning of November and closed the financial year at € 88.95, amounting to a share price increase of 16 % and a market capitalization of € 2.8 billion .

MorphoSys AG shares therefore clearly outperformed the development of the relevant indices, namely the Nasdaq Biotechnology Index (–9 %), the MDAX (–18 %) and the TecDAX (–3 %) in 2018 .

Liquidity and Index Membership

The average daily trading volume in MorphoSys shares on all regulated trading platforms increased by about 45 % in 2018, reaching a volume of € 22.5 million (2017: € 15.6 million). The average daily trading volume on the TecDAX, which contains the 30 largest technology stocks on the Frankfurt Stock Exchange, rose 93 %. In addition, in 2018 MorphoSys shares were included for the first time in the German MDAX index, which comprises the 60 largest companies in terms of market capitalization and turnover on the Frankfurt Stock Exchange behind those that make up the DAX. By the end of 2018, MorphoSys ranked 10th in the TecDAX in terms of market capitalization (2017: 10th) and 14th in terms of trading volume (2017: 12th). In the MDAX, MorphoSys shares ranked 59th in terms of market capitalization and 65th in terms of trading volume (the rank refers to DAX (30) and MDAX (60) listed companies). The average daily trading volume in MorphoSys shares on alternative trading platforms (“dark pools”) in 2018 was
approximately € 16.2 million, or 173,000 shares (2017: approx. 98,700 shares valued at € 6.3 million), representing a year-on-year increase of 156 %.


Key data for the MorphoSys Share (As of December 31)

  2018 2017 2016 2015 2014
Total stockholders´ equity (in million €) 488.4 358.7 415.5 362.7 348.8
Number of shares issued (number) 31,839,572 29,420,785 29,159,770 26,537,682 26,456,834
Market capitalization (in million €) 2,832 2,253 1,422 1,530 2,027
Closing price in € (Xetra) 88.95 76,58 48.75 57.65 76.63
Average daily trading volume (in million €) 22.5 15,6 9.7 14.9 11.9
Average daily trading volume (in % of common stock) 0.77 0,83 0.78 0.87 0.65

Recent voting rights notifications


Institution Contact
Berenberg Ms. Shanshan Xu
Bloomberg Intelligence Ms. Cinney Zhang
Bryan Garnier Mr. Victor Floc’h
Commerzbank Mr. Daniel Wendorff
Deutsche Bank Mr. Konstantinos Aprilakis
EQUI.TS Mr. Thomas Schießle
Goldman Sachs Mr. Graig Suvannavejh       
Guggenheim Securities, LLC Mr. Etzer Darout
HSBC Bank Mr. Steve McGarry
Independent Research GmbH Mr. Tobias Gottschalt
JMP Securities Mr. Jason Butler
J.P.Morgan Cazenove Mr. James Gordon
Kempen & Co. Ms. Suzanne van Voorthuizen
Landesbank Baden-Württemberg Mr. Timo Kürschner
Leerink Mr. Geoffrey Porges
Mainfirst Mr. Marcus Wieprecht
Piper Jaffray Ms. Danielle Brill
Royal Bank of Canada Ms. Zoe Karamanoli


Any opinions, forecasts, estimates, projections or predictions regarding MorphoSys’s performance made by the analysts are theirs alone and do not represent the opinions, forecasts, estimates, projections or predictions of MorphoSys or its management. By providing the names of the analysts or certain information from them, MorphoSys does not imply its endorsement of or concurrence with their reports, conclusions or recommendations. MorphoSys assumes no liability for the accuracy of such information and undertakes no obligation to update it if it is not aware of changes.


American Depositary Shares



Security Paper: American Depositary Shares (ADS)
Ratio: 4 ADSs = 1 ordinary share
U.S. Security Code (Cusip): 617760202
Trading Symbol: MOR
Depositary Bank: The Bank of New York
Local Custodian Bank: The Bank of New York Mellon SANV

ADS administration

All enquiries on ADS holdings should be made to:

BNY Mellon Shareowner Services
PO Box 505000
Louisville, KY 40233-5000
Phone: +1 201 680 6825
Toll free (in the US): +1-888-BNY-ADRS (+1-888-269-2377)

Share Buy-Back

Share Buy-Back March 2016

The Management Board of MorphoSys AG announced on February 24, 2016 with the approval of the Supervisory Board the decision to repurchase its own shares over the stock market for a total purchase price of up to EUR 2.18 million (excluding ancillary costs). The share buy-back will take place between March 3 and March 10, 2016, and is based on the authorization of the Annual General Meeting on May 23, 2014. On the basis of the current share price (EUR 37.47; Xetra closing price as of February 23, 2016), the total purchasing volume amounts to up to 58,179 shares or 0.22% of the registered share capital of the Company.

The Company intends to use the shares for its long-term incentive programs for its Executive Board and the Senior Management Group, but the shares can also be used for all other legally permitted purposes stated in the authorization of the Annual General Meeting of 2014.

The relevant conditions of the shareholders' resolution passed in the Annual General Meeting 2014 on the authorization to acquire and to use its own shares shall apply. The purchase price paid per share may not be more than 10% higher or 20% lower than the Company's share price determined by the opening auction in the Xetra trading system on the day of trading.

The share buy-back has been handled independently of and uninfluenced by the Company through an appointed bank in compliance with the safe-harbor provisions.

The share buy-back program in 2016 was completed on March 4th. Thereby 52,295 shares in total were acquired.


Overview Share Buy-Back Program March 2016

Date Number of Shares Average Price in € Purchased Volume in €
March 3, 2016 13,043 42.483 554,105.77
March 4, 2016 39,252 41.421 1,625,857.09
Total 52,295 41.686 2,179,962.86